Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Evidence-Based Medicine
|
November 17, 2012
HIV consensus guideline recommends antiretroviral treatment regardless of CD4 count, new regimens and possible regimen change for chronic low level viraemia
R Chris Rathbun
Expert Opinion on Investigational Drugs
|
February 28, 2002
Review of the safety and efficacy of voriconazole
Holly L Hoffman, R Chris Rathbun
Expert Opinion on Drug Safety
|
January 26, 2010
Drug interactions with antiretrovirals and warfarin
Michelle D Liedtke, R Chris Rathbun
Pharmaceutics
|
December 7, 2013
Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management
R Chris Rathbun, Michelle D Liedtke
The Annals of Pharmacotherapy
|
March 29, 2002
Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement
R Chris Rathbun, Deanna R Rossi
The Annals of Pharmacotherapy
|
February 7, 2009
Warfarin-antiretroviral interactions
Michelle D Liedtke, R Chris Rathbun
The Annals of Pharmacotherapy
|
November 2, 2012
A probable interaction between warfarin and the antiretroviral TRIO study regimen
Michelle D Liedtke, Amulya Vanguri, R Chris Rathbun
Pharmacotherapy
|
October 23, 2002
Symptomatic orthostasis with extended-release nifedipine and protease inhibitors
Deanna R Rossi, R Chris Rathbun, Leonard N Slater
The Annals of Pharmacotherapy
|
February 19, 2004
Anticonvulsant and antiretroviral interactions
Michelle D Liedtke, Staci M Lockhart, R Chris Rathbun
Expert Review of Anti-Infective Therapy
|
October 16, 2004
Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster
Michelle D Moomaw, Paul Cornea, R Chris Rathbun, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Evidence-Based Medicine
|
November 17, 2012
HIV consensus guideline recommends antiretroviral treatment regardless of CD4 count, new regimens and possible regimen change for chronic low level viraemia
R Chris Rathbun
Expert Opinion on Investigational Drugs
|
February 28, 2002
Review of the safety and efficacy of voriconazole
Holly L Hoffman, R Chris Rathbun
Expert Opinion on Drug Safety
|
January 26, 2010
Drug interactions with antiretrovirals and warfarin
Michelle D Liedtke, R Chris Rathbun
Pharmaceutics
|
December 7, 2013
Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management
R Chris Rathbun, Michelle D Liedtke
The Annals of Pharmacotherapy
|
March 29, 2002
Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement
R Chris Rathbun, Deanna R Rossi
The Annals of Pharmacotherapy
|
February 7, 2009
Warfarin-antiretroviral interactions
Michelle D Liedtke, R Chris Rathbun
The Annals of Pharmacotherapy
|
November 2, 2012
A probable interaction between warfarin and the antiretroviral TRIO study regimen
Michelle D Liedtke, Amulya Vanguri, R Chris Rathbun
Pharmacotherapy
|
October 23, 2002
Symptomatic orthostasis with extended-release nifedipine and protease inhibitors
Deanna R Rossi, R Chris Rathbun, Leonard N Slater
The Annals of Pharmacotherapy
|
February 19, 2004
Anticonvulsant and antiretroviral interactions
Michelle D Liedtke, Staci M Lockhart, R Chris Rathbun
Expert Review of Anti-Infective Therapy
|
October 16, 2004
Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster
Michelle D Moomaw, Paul Cornea, R Chris Rathbun, et al.
Page
of 3